Document is current
Any future updates will be listed below
-
Authors
Stephan, Sirkka B.
Cummings, Carrie L.
Fitzgerald, Katelyn
Stephan, Matthias T. https://orcid.org/0000-0001-8310-0100
-
Funding
Funding for this research was provided by:
Bezos Family Foundation
- License Information
-
More Information
Article History
Received: 20 September 2025
Revised: 10 December 2025
Accepted: 29 January 2026
First Online: 14 February 2026
Competing interests
: MTS is co-founder of, and has received stock options from Persistence Therapeutics (Jupiter Bioventures); he has IP Licensing with Sanofi, Juno Therapeutics (now Bristol Myers Squibb), and Jupiter Bioventures. The remaining authors declare no competing interests.
: This study was conducted exclusively in vitro; therefore obtaining IACUC approval was not applicable.
